Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety

Chimeric antigen receptor (CAR) T cell-based immunotherapy, approved by the US Food and Drug Administration, has shown curative potential in patients with haematological malignancies. However, owing to the lack of control over the location and duration of the anti-tumour immune response, CAR T cell therapy still faces safety challenges arising from cytokine release syndrome and on-target, off-tumour toxicity. Herein, we present the design of light-switchable CAR (designated LiCAR) T cells that allow real-time phototunable activation of therapeutic T cells to precisely induce tumour cell killing. When coupled with imaging-guided, surgically removable upconversion nanoplates that have enhanced near-infrared-to-blue upconversion luminescence as miniature deep-tissue photon transducers, LiCAR T cells enable both spatial and temporal control over T cell-mediated anti-tumour therapeutic activity in vivo with greatly mitigated side effects. Our nano-optogenetic immunomodulation platform not only provides a unique approach to interrogate CAR-mediated anti-tumour immunity, but also sets the stage for developing precision medicine to deliver personalized anticancer therapy. While chimeric antigen receptor (CAR) T cell-based therapy has been approved for clinical use for certain types of blood cancers, it remains difficult to achieve precise spatiotemporal control of the elicited anti-tumour response. Here, the authors propose light-switchable CAR T cells that can be remotely activated by a nano-optogenetic approach, reducing unwanted side effects.

Automated summary

CAR T cell therapy shows curative potential in treating haematological malignancies, but faces safety challenges. Researchers propose a design of light-switchable CAR T cells for real-time activation to induce tumor cell killing accurately.